Intellia Therapeutics(NTLA) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., May 8, 2025 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the first quarter ended March 31, 2025. "Intellia is full steam ahead and making excellent progress across its clinical programs," said Intel ...